Clinical Research Directory
Browse clinical research sites, groups, and studies.
SAMe Trial for Patients With Alcoholic Cirrhosis
Sponsor: Indiana University
Summary
The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B. The primary objective of the study is to test relationship between SAMe (S-adenosylmethionine) supplement on liver function. The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.
Official title: A Multi-center, Randomized, Placebo-controlled Trial of S-Adenosylmethionine (SAMe) in Patients With Alcoholic Cirrhosis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
196
Start Date
2020-10-22
Completion Date
2027-03-01
Last Updated
2026-03-31
Healthy Volunteers
Yes
Conditions
Interventions
Placebo
2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
SAMe 400 mg tablet
SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
Locations (2)
Cedars-Sinai Medical Center
Los Angeles, California, United States
Indiana University Hospital
Indianapolis, Indiana, United States